Table 2 Clinical data on admission and at discharge in each stroke subtype.
Edaravone(-) (n = 83) | Edaravone(+) (n = 93) | |
|---|---|---|
Cardioembolism (%) | 28 (33.7) | 21 (22.6) |
Average lesion size (mm2) | 1359.8 ± 1174.1 | 1391.3 ± 865.9 |
Hospital duration (days) | 39.5 ± 52.1 | 36.2 ± 21.4 |
NIHSS on admission① | 6.9 ± 6.2 | 6.6 ± 6.4 |
at discharge② | 4.6 ± 5.6 | 6.9 ± 10.5 |
Improvement rate (①-②) | 2.8 ± 3.6 | -0.1 ± 9.2 |
Large-artery (%) | 30 (36.1) | 38 (40.9) |
Average lesion size (mm2) | 251.9 ± 285.6 | 235.1 ± 136.6 |
Hospital duration (days) | 24.8 ± 15.2 | 27.6 ± 25.2 |
NIHSS on admission① | 3.8 ± 3.7 | 4.0 ± 4.6 |
at discharge② | 2.3 ± 2.8 | 2.4 ± 3.7 |
Improvement rate (①-②) | 1.6 ± 3.4 | 1.6 ± 3.2 |
Small-vessel(%) | 25 (30.1) | 34 (36.6) |
Average lesion size (mm2) | 67.9 ± 37.2 | 77.6 ± 40.4 |
Hospital duration (days) | 20.8 ± 12.6 | 21.8 ± 14.4 |
NIHSS on admission① | 2.2 ± 2.2 | 4.1 ± 4.6 |
at discharge② | 1.4 ± 1.6 | 2.1 ± 3.2 |
Improvement rate (①-②) | 0.8 ± 1.0 | 2.0 ± 2.8 ‡ |